• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Heterogeneity of serum peptides with immunoactivity detected by a radioimmunoassay for proinsulin-like growth factor-II E domain: description of a free E domain peptide in serum.

作者信息

Daughaday W H, Trivedi B

机构信息

Department of Medicine, Washington University School of Medicine, St. Louis, Missouri 63110.

出版信息

J Clin Endocrinol Metab. 1992 Aug;75(2):641-5. doi: 10.1210/jcem.75.2.1379260.

DOI:10.1210/jcem.75.2.1379260
PMID:1379260
Abstract

We have reported that normal human sera contain immunoactivity (IA) detected by a RIA directed against the first 21 amino acids of the E domain of proinsulin-like growth factor-II (pro-IGF-II). Marked elevations of E-21 IA were found in the serum of patients with nonislet cell hypoglycemia (NICTH) and patients with renal failure receiving chronic hemodialysis. In this paper we describe some of the properties of the E-21 IA of normal and abnormal sera. The E-21 IA eluted from a calibrated acid Sephadex G-50 column as two major peaks. In normal serum the first major peak had a mol wt (Mr) between 14,000-15,000, and the second peak had a Mr between 5,000-6,000. When E-21 IA from serum of a patient with NICTH was similarly studied, most of the IA was present as a Mr 11,000 peak and only a small amount was present as a 5,000-6,000 Mr peak. In contrast, most of the E-21 IA present in the sera of patients on hemodialysis was present in the smaller molecular form, which eluted from a reverse phase column as a single component. This small Mr peak lacked determinants for the IGF-II monoclonal antibody (Amano), for pooled serum IGF-binding proteins, and for the IGF-I receptors on human placental membranes. We suggest that the 15- and 11-kilodalton peaks represent the glycated and unglycated forms of pro-IGF-II (E-21) reported by others. The glycated form appears to predominate in normal serum, whereas the nonglycated form predominates in the serum of patients with NICTH and renal failure. The 5,000-6,000 Mr E-21 IA probably represents a fragment of the free E domain of pro-IGF-II. Its size is consistent with cleavage of the free E domain between Arg46 and Arg47. The accumulation of this E-21 IA in renal failure is evidence that the kidney has a major role in the clearance of this fragment, which is not accomplished by the membranes used in hemodialysis.

摘要

相似文献

1
Heterogeneity of serum peptides with immunoactivity detected by a radioimmunoassay for proinsulin-like growth factor-II E domain: description of a free E domain peptide in serum.
J Clin Endocrinol Metab. 1992 Aug;75(2):641-5. doi: 10.1210/jcem.75.2.1379260.
2
Measurement of derivatives of proinsulin-like growth factor-II in serum by a radioimmunoassay directed against the E-domain in normal subjects and patients with nonislet cell tumor hypoglycemia.采用针对E结构域的放射免疫分析法测定正常人和非胰岛细胞瘤低血糖患者血清中胰岛素样生长因子-II衍生物。
J Clin Endocrinol Metab. 1992 Jul;75(1):110-5. doi: 10.1210/jcem.75.1.1618998.
3
Characterization of proinsulin-like growth factor-II E-region immunoreactivity in serum and other biological fluids.
J Clin Endocrinol Metab. 1993 May;76(5):1095-100. doi: 10.1210/jcem.76.5.8496298.
4
E-domain peptide of rat proinsulin-like growth factor-II: validation of a radioimmunoassay and measurement in culture medium and rat serum.
Endocrinology. 1987 May;120(5):2050-8. doi: 10.1210/endo-120-5-2050.
5
Serum "big insulin-like growth factor II" from patients with tumor hypoglycemia lacks normal E-domain O-linked glycosylation, a possible determinant of normal propeptide processing.肿瘤性低血糖患者血清中的“大胰岛素样生长因子II”缺乏正常的E结构域O-连接糖基化,这可能是正常前肽加工的一个决定因素。
Proc Natl Acad Sci U S A. 1993 Jun 15;90(12):5823-7. doi: 10.1073/pnas.90.12.5823.
6
The E-domain peptide of rat pro-insulin-like growth factor II (proIGF-II): properties of the peptide in serum and production by rat cell lines.大鼠胰岛素样生长因子II(proIGF-II)的E结构域肽:该肽在血清中的特性及大鼠细胞系的产生
Biochim Biophys Acta. 1990 Jan 23;1051(1):6-13. doi: 10.1016/0167-4889(90)90167-c.
7
Immunoreactive proinsulin-like growth factor-II levels in healthy subjects, patients with growth hormone deficiency, and patients with type 1 diabetes: effects of insulin-like growth factor-I and insulin.健康受试者、生长激素缺乏症患者及1型糖尿病患者体内免疫反应性胰岛素样生长因子-II水平:胰岛素样生长因子-I和胰岛素的影响
J Clin Endocrinol Metab. 1994 Dec;79(6):1576-81. doi: 10.1210/jcem.79.6.7989458.
8
Antibodies directed against the E region of pro-insulin-like growth factor-II used to evaluate non-islet cell tumor-induced hypoglycemia.用于评估非胰岛细胞瘤所致低血糖症的抗胰岛素样生长因子-II E区抗体。
Clin Chem. 2002 Oct;48(10):1739-50.
9
Serum high molecular weight form of insulin-like growth factor II from patients with non-islet cell tumor hypoglycemia is O-glycosylated.非胰岛细胞瘤低血糖症患者血清中高分子量形式的胰岛素样生长因子II是O-糖基化的。
J Clin Endocrinol Metab. 1998 Aug;83(8):2875-7. doi: 10.1210/jcem.83.8.5021.
10
Characterization of new monoclonal antibodies to human insulin-like growth factor-II and their application in western immunoblot analysis.新型抗人胰岛素样生长因子-II单克隆抗体的特性及其在蛋白质免疫印迹分析中的应用。
J Clin Endocrinol Metab. 1993 Aug;77(2):510-7. doi: 10.1210/jcem.77.2.7688378.

引用本文的文献

1
Non-islet cell tumour hypoglycaemia in a patient with a well-differentiated gastric neuroendocrine tumour.一名患有高分化胃神经内分泌肿瘤的患者出现非胰岛细胞瘤低血糖症。
BMJ Case Rep. 2019 Sep 16;12(9):e231069. doi: 10.1136/bcr-2019-231069.
2
Doege-Potter syndrome: A review of the literature including a new case report.多伊格-波特综合征:文献综述并附一例新病例报告
Medicine (Baltimore). 2017 Jul;96(27):e7417. doi: 10.1097/MD.0000000000007417.
3
Non-islet cell tumor-induced hypoglycemia: a report of five cases and brief review of the literature.
非胰岛细胞瘤所致低血糖症:5例报告并文献简要回顾
Endocrinol Diabetes Metab Case Rep. 2013;2013:130046. doi: 10.1530/EDM-13-0046. Epub 2013 Nov 20.
4
Differential effect of proIGF-II and IGF-II on resveratrol induced cell death by regulating survivin cellular localization and mitochondrial depolarization in breast cancer cells.前胰岛素样生长因子-II(proIGF-II)和胰岛素样生长因子-II(IGF-II)通过调节乳腺癌细胞中生存素的细胞定位和线粒体去极化对白藜芦醇诱导的细胞死亡产生不同影响。
Growth Factors. 2007 Dec;25(6):363-72. doi: 10.1080/08977190801886905.
5
Preptin derived from proinsulin-like growth factor II (proIGF-II) is secreted from pancreatic islet beta-cells and enhances insulin secretion.源自胰岛素样生长因子II(proIGF-II)的前胰岛素原从胰岛β细胞分泌,并增强胰岛素分泌。
Biochem J. 2001 Dec 1;360(Pt 2):431-9. doi: 10.1042/0264-6021:3600431.
6
Serum "big insulin-like growth factor II" from patients with tumor hypoglycemia lacks normal E-domain O-linked glycosylation, a possible determinant of normal propeptide processing.肿瘤性低血糖患者血清中的“大胰岛素样生长因子II”缺乏正常的E结构域O-连接糖基化,这可能是正常前肽加工的一个决定因素。
Proc Natl Acad Sci U S A. 1993 Jun 15;90(12):5823-7. doi: 10.1073/pnas.90.12.5823.